控释吗啡治疗癌痛的临床观察

Clinical observations on controlled-release morphine in cancer pain.

作者信息

Ventafridda V, Saita L, Barletta L, Sbanotto A, De Conno F

出版信息

J Pain Symptom Manage. 1989 Sep;4(3):124-9. doi: 10.1016/0885-3924(89)90005-5.

Abstract

The authors report the data from two studies on the use of controlled-release morphine sulphate tablets for cancer pain relief. This preparation allows just two administrations per day, in comparison with immediate release oral aqueous morphine solution. The first study, a randomized trial carried out on 70 patients suffering from advanced cancer pain, evaluated the analgesic efficacy and side effects of this drug. The second, an open study of 113 patients, assessed analgesic efficacy, incidence of side effects, and the effects of age on dose. The analgesia provided by controlled-release morphine administration proved to be superimposable to those of the oral aqueous morphine solution. Moreover, the use of controlled-release morphine was associated with a statistically significant reduction of some side effects. Ninety-one percent of patients needed controlled-release morphine every 12 hr, while 9% required it every 8 hr.

摘要

作者报告了两项关于使用硫酸吗啡控释片缓解癌症疼痛的研究数据。与即释口服水吗啡溶液相比，这种制剂每天只需服用两次。第一项研究是对70名晚期癌症疼痛患者进行的随机试验，评估了该药物的镇痛效果和副作用。第二项研究是对113名患者进行的开放性研究，评估了镇痛效果、副作用发生率以及年龄对剂量的影响。结果证明，服用控释吗啡所提供的镇痛效果与口服水吗啡溶液的镇痛效果相当。此外，使用控释吗啡与某些副作用在统计学上的显著减少相关。91%的患者每12小时需要服用控释吗啡，而9%的患者每8小时需要服用一次。